¼¼°èÀÇ ºñ¹ÙÀÌ·¯½º ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀå º¸°í¼­(2025³â)
Non-Viral Drug Delivery Systems Global Market Report 2025
»óǰÄÚµå : 1769681
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,310,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,121,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,932,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ºñ¹ÙÀÌ·¯½º ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ ±Þ¼ºÀåÀÌ Àü¸ÁµÉ ¿¹Á¤ÀÔ´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¼ºÀåÀº Ç¥Àû Ä¡·áÀÇ Ã¤Åà Áõ°¡, ¾à¹° Àü´Þ Çõ½Å¿¡ ´ëÇÑ ÅõÀÚ È®´ë, ºñħ½ÀÀû Ä¡·á ¹æ¹ý¿¡ ´ëÇÑ °ü½É Áõ°¡, Àΰø Áö´ÉÀÇ ÅëÇÕ °­È­, Áö¼Ó ¹æÃâ ÀǾàǰ Á¦Çü¿¡ ´ëÇÑ Çʿ伺 Áõ°¡¿¡ ÀÇÇØ ÃËÁøµÉ °ÍÀÔ´Ï´Ù. ÀÌ ±â°£ µ¿¾È ¿¹»óµÇ´Â ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ³ª³ë ij¸®¾î ±â¼úÀÇ ¹ßÀü, Â÷¼¼´ë »ýü Àç·áÀÇ °³¹ß, mRNA Àü´Þ ½Ã½ºÅÛÀÇ Çõ½Å, ½º¸¶Æ® ¾à¹° Àü´Þ ÀåÄ¡ÀÇ ÅëÇÕ, À¯ÀüÀÚ ÆíÁý Àü´Þ ±â¼úÀÇ °³¼± µîÀÌ ÀÖ½À´Ï´Ù.

¸ÂÃãÇü ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ºñ¹ÙÀÌ·¯½º ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀÌ ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¸ÂÃãÇü ÀǾàǰÀº °³ÀÎÀÇ À¯ÀüÀû Ư¼º, »ýȰ ¹æ½Ä ¹× ȯ°æÀû ¿äÀο¡ ¸ÂÃãÈ­µÈ Ä¡·á ¹æ¹ýÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¼ö¿ä Áõ°¡´Â °¢ ȯÀÚÀÇ Áúº´ÀÇ ±Ùº» ¿øÀÎÀ» ÇØ°áÇÏ´Â º¸´Ù È¿°úÀûÀÎ Ä¡·á¹ýÀÇ ÀáÀç·Â¿¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ºñ¹ÙÀÌ·¯½º ½Ã½ºÅÛÀº ¾à¹°À̳ª À¯ÀüÀÚ¸¦ ¼¼Æ÷¿¡ ¾ÈÀüÇÏ°Ô Àü´ÞÇÏ¿© À§ÇèÀ» ÃÖ¼ÒÈ­Çϰí Ä¡·áÀÇ Á¤È®¼ºÀ» ³ôÀÓÀ¸·Î½á ¸ÂÃãÇü ÀǾàǰÀ» Áö¿øÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 2¿ù, ¹Ì±¹¿¡ º»»ç¸¦ µÐ ºñ¿µ¸® ´ÜüÀÎ Personalized Medicine CoalitionÀº FDA°¡ 2023³â¿¡ Èñ±Í Áúȯ ȯÀÚ¸¦ À§ÇÑ 16°³ÀÇ »õ·Î¿î ¸ÂÃãÇü Ä¡·á¹ýÀ» ½ÂÀÎÇß´Ù°í ¹àÇû½À´Ï´Ù. ÀÌ´Â 2022³â¿¡ ½ÂÀÎµÈ 6°³º¸´Ù Áõ°¡ÇÑ ¼öÄ¡ÀÔ´Ï´Ù. ±× °á°ú, ¸ÂÃãÇü ÀǾàǰ¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö¸é¼­ ºñ¹ÙÀÌ·¯½º ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

ºñ¹ÙÀÌ·¯½º ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷µéÀº RNA ±â¹Ý Ä¡·á¹ýÀÇ °³¹ß ¹× Àü´ÞÀ» ÃËÁøÇϱâ À§ÇØ »çÀü ÃÖÀûÈ­µÈ ÀÌ¿ÂÈ­ ÁöÁú È¥ÇÕ ½Ã½ºÅÛ°ú °°Àº ÷´Ü ±â¼úÀÇ »ç¿ëÀ» °­Á¶Çϰí ÀÖ½À´Ï´Ù. ÀÌ Á¦Çü ±â¼úÀ» ÅëÇØ RNA ºÐÀÚ¸¦ ÁöÁú ³ª³ë ÀÔÀÚ ³»¿¡ È¿À²ÀûÀ¸·Î ĸ½¶È­ÇÏ¿© ¾ÈÁ¤¼º, À¯È¿ ¼ººÐ º¸È£ ¹× Ç¥Àû À¯ÀüÀÚ Àü´ÞÀ» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 9¿ù, ¹Ì±¹¿¡ º»»ç¸¦ µÐ »ý¸í°øÇÐ ±â¾÷ÀÎ Cytiva´Â ÀÚ»çÀÇ NanoAssemblr Ignite ¹× Ignite+ Ç÷§Æû°ú ȣȯµÇ´Â RNA Àü´Þ LNP ŰƮ¸¦ Ãâ½ÃÇß½À´Ï´Ù. ÀÌ ½Ã½ºÅÛÀº Áï½Ã »ç¿ë °¡´ÉÇÑ ÀÌ¿ÂÈ­ ÁöÁú È¥ÇÕ¹°À» Ư¡À¸·Î Çϸç, ½Å¼ÓÇÑ RNA À¯È¿ ºÎÇÏ ½ºÅ©¸®´× ¹× Àü´Þ °ËÁõÀ» °¡´ÉÇÏ°Ô ÇÏ¿©, ƯÈ÷ Àü¿°º´ ¹é½Å °³¹ß¿¡ À¯¿ëÇÕ´Ï´Ù. ÀÌ ½Ã½ºÅÛÀº ÀÚµ¿È­µÈ ¹Ì¼¼À¯Ã¼ Ç÷§Æû°ú ÅëÇյǰí, GMP µî±Þ Àç·á¸¦ »ç¿ëÇÑ È®Àå °¡´ÉÇÑ Á¦Á¶¸¦ Áö¿øÇϸç, ¹ß°ßºÎÅÍ ÀÓ»ó ½ÃÇè¿¡ À̸£±â±îÁö »ç¿ëÀÚ¸¦ ¾È³»ÇÏ´Â ÇÁ·ÎÅäÄݰú °³³ä Áõ¸í µ¥ÀÌÅ͸¦ Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå : ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ªÀüÀï°ú °ü¼¼, ±×¸®°í Äڷγª 19 ¹× ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°, ±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

HBR
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Non-viral drug delivery systems are methods used to administer therapeutic agents into the body without relying on viral vectors. These systems utilize various physical, chemical, or mechanical approaches-such as nanoparticles, liposomes, or polymer-based carriers-to effectively transport drugs to specific target areas. Their primary goal is to minimize the risks commonly associated with viral delivery methods, including immune responses and insertional mutagenesis. This strategy improves the overall efficacy of treatments while enhancing patient safety for a wide range of medical conditions.

Non-viral drug delivery systems are primarily used to deliver two main categories of molecules: biologics and small molecules. Biologics are therapeutic agents derived from living organisms and include proteins, peptides, monoclonal antibodies, as well as nucleic acid-based treatments like RNA and DNA. The biologics delivered using these systems include ribonucleic acid (RNA), deoxyribonucleic acid (DNA), proteins or peptides, and antibodies. The major end users of these systems are pharmaceutical and biotechnology companies, academic and research institutions, contract development and manufacturing organizations (CDMOs), and hospitals and clinics.

The non-viral drug delivery systems market research report is one of a series of new reports from The Business Research Company that provides non-viral drug delivery systems market statistics, including the non-viral drug delivery systems industry global market size, regional shares, competitors with the non-viral drug delivery systems market share, detailed non-viral drug delivery systems market segments, market trends, and opportunities, and any further data you may need to thrive in the non-viral drug delivery systems industry. This non-viral drug delivery systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The non-viral drug delivery systems market size has grown rapidly in recent years. It will grow from $8.60 billion in 2024 to $9.84 billion in 2025 at a compound annual growth rate (CAGR) of 14.4%. The growth during the historical period is due to various drivers such as the increasing demand for safer gene therapy options, advancements in nanotechnology, a higher prevalence of chronic diseases, a stronger focus on personalized medicine, and enhanced regulatory backing for non-viral platforms.

The non-viral drug delivery systems market size is expected to see rapid growth in the next few years. It will grow to $16.72 billion in 2029 at a compound annual growth rate (CAGR) of 14.2%. Growth in the forecast period will be driven by the increasing adoption of targeted therapies, greater investment in drug delivery innovation, rising interest in non-invasive treatment methods, enhanced integration of artificial intelligence, and the growing need for sustained-release drug formulations. Key trends anticipated during this period include progress in nanocarrier technologies, development of next-generation biomaterials, innovations in mRNA delivery systems, incorporation of smart drug delivery devices, and improvements in gene editing delivery techniques.

The rising demand for personalized medicines is anticipated to drive the growth of the non-viral drug delivery systems market. Personalized medicine is a treatment approach tailored to an individual's genetic profile, lifestyle, and environmental factors. This growing demand is fueled by the potential for more effective treatments that address the root causes of disease in each patient. Non-viral systems support personalized medicine by delivering drugs or genes safely to cells, thereby minimizing risks and enhancing treatment accuracy. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based non-profit organization, reported that the FDA approved 16 new personalized therapies for patients with rare diseases in 2023, up from six approvals in 2022. As a result, the increasing preference for personalized medicines is contributing to the expansion of the non-viral drug delivery systems market.

Key companies in the non-viral drug delivery system market are emphasizing the use of advanced technologies, such as pre-optimized ionizable lipid mix systems, to facilitate the development and delivery of RNA-based therapies. This formulation technology allows RNA molecules to be efficiently encapsulated within lipid nanoparticles, ensuring stability, payload protection, and targeted gene delivery. For instance, in September 2024, Cytiva, a U.S.-based biotechnology firm, introduced an RNA delivery LNP kit that is compatible with its NanoAssemblr Ignite and Ignite+ platforms. The system features a ready-to-use ionizable lipid mix that enables swift RNA payload screening and validation for delivery, particularly useful in vaccine development for infectious diseases. It integrates with automated microfluidic platforms, supports scalable manufacturing using GMP-grade materials, and provides protocols and proof-of-concept data to guide users from discovery through clinical trials.

In September 2023, SOHM Inc., a U.S.-based pharmaceutical firm, acquired ABBIE from CGA 369 for $10 million to enhance its non-viral gene-editing capabilities. This acquisition bolsters SOHM's ability to deliver large genetic payloads through integrase-based, non-viral platforms. ABBIE is being developed for off-the-shelf gene-editing kits, with plans for commercialization in 2024 and human trials expected by the end of 2025. CGA 369, also a U.S.-based biotechnology company, focuses on non-viral, integrase-driven gene-editing and genetic delivery solutions.

Major players in the non-viral drug delivery systems market are Evonik Industries AG, Cytiva, Arcturus Therapeutics Holdings Inc., CureVac N.V., PolyPid Ltd, Ethris GmbH, Entos Pharmaceuticals Inc., Liquidia Technologies Inc., ReCode Therapeutics Inc., Enable Injections Inc., GenEdit Inc., N4 Pharma Plc, Hopewell Therapeutics Inc., Tiba Biotech LLC, Vesigen Therapeutics Inc., Carmine Therapeutics Inc., Evox Therapeutics Ltd, InnoCore Pharmaceuticals BV, Nanomerics Ltd, DelSiTech Ltd, and Curapath Inc.

North America was the largest region in the non-viral drug delivery systems market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in non-viral drug delivery systems report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the non-viral drug delivery systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-viral drug delivery systems market consists of sales of exosomes, cell-penetrating peptides, and nanocrystals. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Viral Drug Delivery Systems Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-viral drug delivery systems market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for non-viral drug delivery systems ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-viral drug delivery systems market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Non-Viral Drug Delivery Systems Market Characteristics

3. Non-Viral Drug Delivery Systems Market Trends And Strategies

4. Non-Viral Drug Delivery Systems Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Non-Viral Drug Delivery Systems Growth Analysis And Strategic Analysis Framework

6. Non-Viral Drug Delivery Systems Market Segmentation

7. Non-Viral Drug Delivery Systems Market Regional And Country Analysis

8. Asia-Pacific Non-Viral Drug Delivery Systems Market

9. China Non-Viral Drug Delivery Systems Market

10. India Non-Viral Drug Delivery Systems Market

11. Japan Non-Viral Drug Delivery Systems Market

12. Australia Non-Viral Drug Delivery Systems Market

13. Indonesia Non-Viral Drug Delivery Systems Market

14. South Korea Non-Viral Drug Delivery Systems Market

15. Western Europe Non-Viral Drug Delivery Systems Market

16. UK Non-Viral Drug Delivery Systems Market

17. Germany Non-Viral Drug Delivery Systems Market

18. France Non-Viral Drug Delivery Systems Market

19. Italy Non-Viral Drug Delivery Systems Market

20. Spain Non-Viral Drug Delivery Systems Market

21. Eastern Europe Non-Viral Drug Delivery Systems Market

22. Russia Non-Viral Drug Delivery Systems Market

23. North America Non-Viral Drug Delivery Systems Market

24. USA Non-Viral Drug Delivery Systems Market

25. Canada Non-Viral Drug Delivery Systems Market

26. South America Non-Viral Drug Delivery Systems Market

27. Brazil Non-Viral Drug Delivery Systems Market

28. Middle East Non-Viral Drug Delivery Systems Market

29. Africa Non-Viral Drug Delivery Systems Market

30. Non-Viral Drug Delivery Systems Market Competitive Landscape And Company Profiles

31. Non-Viral Drug Delivery Systems Market Other Major And Innovative Companies

32. Global Non-Viral Drug Delivery Systems Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-Viral Drug Delivery Systems Market

34. Recent Developments In The Non-Viral Drug Delivery Systems Market

35. Non-Viral Drug Delivery Systems Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â